NCT06962722 The Effect of Upper Limb Low-intensity Motor Control Training Program on Cognitive Function in Healthy Older Adults
| NCT ID | NCT06962722 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Nottingham |
| Condition | Cognitive Impairment |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2023-09-01 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This healthy volunteer intervention study is designed to evaluate the effectiveness of upper limb motor control training (uMCT) on physical and cognitive functions in older adults. The primary objectives of the study are twofold: Assess the Impact on Physical and Neuromuscular Function: The study seeks to determine whether uMCT positively influences physical performance, including motor coordination and neuromuscular function, in older adults. Assessment the Impact on Cognitive Function: The study aims to investigate whether uMCT enhances cognitive abilities in older adults. In addition to these main goals, the study will also assess the feasibility and safety of implementing uMCT in an older adult population. The main questions it aims to answer are: Does uMCON training have a positive effect on physical function and neuromuscular function in older adults? Does uMCON training have a positive effect on cognitive function in older adults? The researchers designed this study to show whether uMCON training works on physical function (balance, gait, and so on) and cognition in older adults. Participants will come to Derby Royal Hospital Medical School to attend uMCON training three days a week for 1 month. They will attend pre-training, post-training, and follow-up (after 1 month) control assessment sessions.
Eligibility Criteria
Inclusion Criteria: * • Willing and able to give informed consent for participation in the study * Aged between 65-85 years Exclusion Criteria: * • Diagnosis of cognitive impairment * Current or recent (\<5y) malignancy * History of or current psychiatric illness * History of or current neurological condition (e.g., epilepsy, Parkinsons disease, cerebrovascular disease) * Severe respiratory disease (e.g., uncontrolled asthma, COPD, pulmonary hypertension) * Active cardiovascular disease: Uncontrolled hypertension (BP\>160/100mmHg); Recent (\<12mo) cardiac event; Heart failure (Class III/IV); Significant arrhythmia; Unstable angina * Metabolic disease: Untreated hyper/hypo-parathyroidism; Cushing's disease; Type 1 or 2 diabetes * Significant musculoskeletal disorders (based on clinical opinion) * Family history of early (\<55y) death from cardiovascular disease
Contact & Investigator
Hatice Sirin Ekici, PhD
STUDY DIRECTOR
The University of Nottingham
Frequently Asked Questions
Who can join the NCT06962722 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 85 Years, studying Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06962722 currently recruiting?
Yes, NCT06962722 is actively recruiting participants. Contact the research team at beth.phillips@nottingham.ac.uk for enrollment information.
Where is the NCT06962722 trial being conducted?
This trial is being conducted at Derby, United Kingdom.
Who is sponsoring the NCT06962722 clinical trial?
NCT06962722 is sponsored by University of Nottingham. The principal investigator is Hatice Sirin Ekici, PhD at The University of Nottingham. The trial plans to enroll 24 participants.